Psychiatric Digital Biomarkers Market Size & Growth Forecast 2026–2035, By Segments (Type, Clinical Practice, End-use), Regional Demand Trends (North America, Asia Pacific, Europe), Key Country Insights (U.S., Japan, South Korea, Germany, France, Italy), and Competitive Landscape
Market Size and Growoth Outlook
Psychiatric Digital Biomarkers Market size was more than USD 746.74 Million in 2025 and is set to grow at a 23.7% CAGR between 2026 and 2035, attaining USD 6.26 Billion by 2035. The industry revenue for 2026 is estimated at USD 907.45 million.
Get more details on this report
Request Free Sample ReportPsychiatric Digital Biomarkers Market Intelligence Snapshot
Regional Market Dynamics
- North America leads with 61.32% share due to a mature digital health ecosystem, strong integration of remote monitoring into clinical workflows, and widespread use of connected mental health platforms.
- Asia Pacific is the fastest-growing region at 26.07% CAGR, driven by rising smartphone and wearable penetration enabling continuous symptom tracking, remote engagement, and scalable mental health services.
Segment Momentum
- Wearable devices accounted for 42.29% of the market in 2025 because they enable continuous passive data collection and real-world behavioral monitoring with minimal patient effort, supporting sustained psychiatric assessment.
- Monitoring psychiatric digital biomarkers are growing fastest as care increasingly emphasizes continuous symptom tracking, treatment response, and relapse monitoring, creating stronger demand for longitudinal patient observation beyond initial diagnosis.
Market Expansion Drivers
- Rising mental health disorder prevalence accelerating demand for continuous digital monitoring solutions.
- Growing wearable device and mobile health app adoption expanding psychiatric biomarker data collection.
- AI-driven behavioral analytics improving early detection and personalized mental healthcare interventions.
Leading Market Participants
Global Market Forecast Snapshot
Market Outlook
Prominent companies in the psychiatric digital biomarkers market include Koneksa Health, Inc. (United States), Empatica Inc. (United States), VivoSense, Inc. (United States), IXICO plc (United Kingdom), Sonde Health, Inc. (United States), Clario (United States), Biogen Inc. (United States), Altoida, Inc. (United States), Mindstrong Health, Inc. (United States), Holmusk Technologies Pte. Ltd. (Singapore).Regional and Segment Outlook
North AmericaMarket Growth Drivers and Industry Trends
As the incidence and recognition of depression, anxiety, bipolar disorder, schizophrenia, and related conditions increase, care teams are facing a larger patient base that cannot be managed effectively through episodic consultations alone. This is pushing the psychiatric digital biomarkers market toward tools that capture passive, longitudinal signals such as sleep disruption, activity changes, speech patterns, and smartphone interaction behavior, because these indicators help clinicians identify deterioration between visits and prioritize intervention earlier. Payers, providers, and digital health companies are responding by integrating continuous monitoring into care pathways, driving market development for psychiatric digital biomarkers that support risk stratification, relapse detection, and treatment tracking in real-world settings.
Growing wearable device and mobile health app adoption expanding psychiatric biomarker data collection
Wider use of smartwatches, fitness bands, smartphones, and mental wellness apps is making behavioral and physiological data far more accessible for psychiatric assessment, which is directly aiding market expansion for the psychiatric digital biomarkers market. The practical effect is a larger and more frequent stream of measurable inputs—movement, heart rate variability, sleep patterns, geolocation consistency, screen time, and communication behavior—that developers can convert into psychiatric biomarker models without requiring specialized clinical hardware. This consumer technology base lowers data acquisition barriers, increases patient participation in remote monitoring programs, and encourages healthcare platforms to build biomarker-enabled services around devices that many users already own.
AI-driven behavioral analytics improving early detection and personalized mental healthcare interventions
Advances in AI are making raw behavioral data clinically useful by identifying patterns that would be difficult to detect through manual review, a shift that is increasing market adoption for the psychiatric digital biomarkers market. In practice, machine learning models can detect subtle deviations in language, mobility, sleep regularity, social engagement, or device usage that correlate with symptom escalation, allowing providers to intervene before a crisis or relapse becomes more visible. The same analytical capability also supports more individualized treatment adjustments, since psychiatric digital biomarkers can be interpreted in the context of each patient’s baseline behavior rather than against broad population averages alone.
| Growth Driver | Impact on CAGR | Regulatory Influence | Geographic Relevance | Adoption Rate | Impact Timeline |
|---|---|---|---|---|---|
| Rising mental health disorder prevalence accelerating demand for continuous digital monitoring solutions | 2.00% | High | North America, Europe | High | Near Term |
| Growing wearable device and mobile health app adoption expanding psychiatric biomarker data collection | 1.80% | Moderate | North America, Asia Pacific | High | Mid Term |
| AI-driven behavioral analytics improving early detection and personalized mental healthcare interventions | 1.50% | Moderate | Europe, North America | Emerging | Mid Term |
Unlock insights tailored to your business with our bespoke market research solutions.
Click to get your customized report now.
Regional Demand Dynamics
North America held the leading position in 2025, accounting for a 61.32% share of the psychiatric digital biomarkers market. This leadership is bolstered by the region’s established digital health ecosystem, stronger integration of remote monitoring and data-driven mental health assessment into clinical workflows, and broader use of connected devices and mobile health platforms in psychiatric care. In practice, these conditions make it easier for healthcare providers, technology developers, and research institutions to generate, validate, and apply behavioral and physiological data for diagnosis support and patient monitoring, reinforcing sustained regional demand.
Asia Pacific is projected to expand at a 26.07% CAGR over the forecast period, driven by the rapid uptake of digital health tools and rising adoption of technology-enabled mental health services across the region. Growth in the psychiatric digital biomarkers market is being fueled by widening access to smartphones and wearable devices, which improves the practicality of continuous symptom tracking and remote patient engagement outside traditional care settings. As providers and digital platforms increasingly use real-world patient data to support earlier detection and ongoing management of psychiatric conditions, regional adoption is accelerating through more accessible and scalable care delivery models.
| Parameter | North America | Asia Pacific | Europe | Latin America | MEA |
|---|---|---|---|---|---|
| Innovation Hub i Scale Nascent Developing Advanced | |||||
| Cost-Sensitive Region i Scale Low Medium High | |||||
| Regulatory Environment i Scale Restrictive Neutral Supportive | |||||
| Demand Drivers i Scale Weak Moderate Strong | |||||
| Development Stage i Scale Emerging Developing Developed | |||||
| Adoption Rate i Scale Low Medium High | |||||
| New Entrants / Startups i Scale Sparse Moderate Dense | |||||
| Macro Indicators i Scale Weak Stable Strong |
Key Country Insights
Germany 🇩🇪
Clinical Validation FocusGermany emphasizes clinically validated psychiatric digital biomarkers that align with evidence-based mental healthcare and digital health regulations. Research institutions and healthcare providers in Germany are strengthening collaborations to improve the adoption of objective digital assessment tools within psychiatric practice.
France 🇫🇷
Data-Driven Mental CareFrance is encouraging the use of psychiatric digital biomarkers within research and clinical settings to improve objective mental health evaluation. Healthcare organizations in France are focusing on secure data collection and validated digital assessment methods that support routine psychiatric decision-making.
Italy 🇮🇹
Digital Psychiatry AdoptionItaly is incorporating psychiatric digital biomarkers into broader digital health initiatives aimed at improving mental healthcare delivery. Clinical centers in Italy are expanding the use of remote monitoring technologies that provide continuous patient insights and support individualized treatment planning.
Japan 🇯🇵
Remote Behavioral MonitoringJapan is expanding the use of psychiatric digital biomarkers to support continuous patient monitoring and address growing mental healthcare needs. Healthcare organizations in Japan are evaluating digital platforms that combine behavioral data with clinical workflows to improve long-term patient management.
South Korea 🇰🇷
AI-Enabled Psychiatric AssessmentSouth Korea is integrating artificial intelligence with digital biomarker platforms to strengthen psychiatric assessment and patient monitoring. Healthcare providers in South Korea continue adopting connected digital health solutions that support earlier intervention and more personalized mental health management.
United States 🇺🇸
Digital Mental Health IntegrationThe U.S. psychiatric digital biomarkers market is advancing through the integration of wearable devices, smartphone-based monitoring, and AI-supported analytics into behavioral health programs. Healthcare providers in the U.S. are prioritizing clinically validated digital tools that complement diagnosis, treatment monitoring, and personalized psychiatric care.
Segment Leadership and Growth Trends
Psychiatric Digital Biomarkers Market Share (%), Type, 2025
Go beyond the chart, access full insights & data tables
Request Free Sample ReportWearable led the psychiatric digital biomarkers market in 2025, accounting for a 42.29% share. Its position is supported by the practical advantage of continuous passive data collection, which is especially valuable in psychiatric assessment where behavioral and physiological patterns often need to be observed over time rather than at isolated clinical touchpoints. In the psychiatric digital biomarkers market, wearable devices also benefit from their ability to capture real-world signals with relatively limited patient effort, making them well suited for structured monitoring environments and sustained data generation.
Mobile Based Applications are emerging as the fastest-growing segment in the psychiatric digital biomarkers market because they align more directly with scalable deployment and everyday patient interaction. Their momentum is being encouraged by the ease of software-based distribution through widely used smartphones, which lowers adoption friction compared with dedicated hardware alternatives. As psychiatric care increasingly depends on frequent symptom tracking and real-world behavioral inputs, mobile based applications are seeing wider adoption by fitting more naturally into daily routines while enabling broader reach across patient populations.
Clinical Practice Segment Analysis: Diagnostic Psychiatric Digital Biomarkers (Largest Segment) vs Monitoring Psychiatric Digital Biomarkers (Fastest-Growing Segment)
Diagnostic Psychiatric Digital Biomarkers held the strongest position in the psychiatric digital biomarkers market in 2025 with a 33.07% share. This leadership reflects the central role of diagnostic support in psychiatric workflows, where objective digital measures are increasingly used to complement clinical evaluation and strengthen decision-making at the point of assessment. Within the psychiatric digital biomarkers market, demand remains concentrated around tools that help identify measurable patterns linked to psychiatric conditions, since diagnosis continues to be the primary gateway for treatment planning and care pathway selection.
Monitoring Psychiatric Digital Biomarkers represent the fastest-growing segment in the psychiatric digital biomarkers market as care models place greater emphasis on longitudinal observation beyond the initial diagnosis. Their growth is supported by the practical need to track symptom variation, treatment response, and relapse indicators over time, which makes ongoing monitoring more actionable than episodic assessment alone. Compared with diagnostic-focused use cases, monitoring applications are gaining momentum because psychiatric conditions often require continuous oversight, creating stronger demand for biomarkers that can reflect changes in patient status between clinical visits.
| Segment | Sub-Segment | Largest Segment | Fastest Growing |
|---|---|---|---|
| Type | Wearable, Mobile Based Applications, Sensors, Others | Wearable | Mobile Based Applications |
| Clinical Practice | Diagnostic Psychiatric Digital Biomarkers, Monitoring Psychiatric Digital Biomarkers, Predictive and Prognostic Psychiatric Digital Biomarkers, Others | Diagnostic Psychiatric Digital Biomarkers | Monitoring Psychiatric Digital Biomarkers |
| End-use | Healthcare Companies, Healthcare Providers, Payers, Others | Healthcare Companies | Payers |
Competitive Landscape and Market Positioning
1. Koneksa Health Inc. (United States)
2. Empatica Inc. (United States)
3. VivoSense Inc. (United States)
4. IXICO plc (United Kingdom)
5. Sonde Health Inc. (United States)
6. Clario (United States)
7. Biogen Inc. (United States)
8. Altoida Inc. (United States)
9. Mindstrong Health Inc. (United States)
10. Holmusk Technologies Pte. Ltd. (Singapore)
The psychiatric digital biomarkers market is progressing through the integration of artificial intelligence, wearable technologies, and behavioral data analytics. Research initiatives are increasingly focused on improving early detection, continuous monitoring, and personalized mental health assessment tools. Strategic collaborations between digital health innovators and clinical research organizations are further accelerating technological development and expanding application potential.
| Company | Market Share | Company Revenue | Revenue CAGR (%) | Product Portfolio | Geographic Presence | Innovation / R&D Focus | Strategic Developments |
|---|---|---|---|---|---|---|---|
| No companies available. | |||||||
Industry Development/News
| Company Name | Date | Key Development |
|---|---|---|
| Indivi | Mar-24 | Indivi entered a multi-year partnership with Biogen to license the Konectom™ smartphone-based platform for neurological research. By integrating this technology with its dreaMS™ platform, Indivi is developing advanced digital endpoints for Parkinson’s disease, leveraging machine learning to derive precise, objective measures of disease progression that improve upon traditional, subjective clinical assessment tools in neuroscience R&D. |
| Beacon Biosignals | Apr-24 | Beacon Biosignals partnered with Takeda to utilize its FDA-cleared EEG headband and AI-driven analytics platform in sleep disorder clinical trials. This collaboration enables the collection of high-fidelity, laboratory-grade sleep data directly from patients' homes, significantly enhancing the ability to objectively monitor treatment efficacy and advance the adoption of digital biomarkers in CNS-related therapeutic development. |
| Tris Pharma | Apr-24 | Tris Pharma partnered with Braingaze Ltd. to launch Tris Digital Health, a dedicated business unit focused on digital therapeutics and diagnostics for ADHD and other neurological conditions. This move reflects a strategic shift toward integrating objective, gaze-tracking digital biomarkers into the diagnosis and management of neurodevelopmental disorders, aiming to improve therapeutic precision and patient-specific treatment protocols. |
| Empatica | Feb-24 | Empatica was selected as a technology partner by the U.S. Department of Defense (DoD) for the Defense Health Agency’s PTSD Drug Treatment Program. By deploying its wearable monitoring technology to gather physiological data, the company supports the development of objective biomarkers for tracking stress and treatment responses, reinforcing the utility of continuous physiological monitoring in complex mental health clinical trials. |
| Koneksa Health | Feb-22 | Koneksa Health secured USD 45 million in Series C funding to accelerate the development of its digital biomarker platform and clinical data integration capabilities. The investment supports the expansion of its clinical-grade sensor network and data analytics infrastructure, which enables pharmaceutical companies to collect real-time behavioral and physiological data, reducing clinical trial costs and improving patient stratification. |
Explore This Report
Click a section of the wheel — or its numbered marker — to preview the custom segmentation, custom table of contents, or related reports available for this market.
Psychiatric Digital Biomarkers Market — Custom Segments
| Segment | Sub-Segment |
|---|---|
| No segment data available. | |
Psychiatric Digital Biomarkers Market — report.custom
| Custom Chapter | Custom Details | ||
|---|---|---|---|
| No custom TOC data available. | |||
Need a different cut of the data?
Request Custom ResearchHow big is the psychiatric digital biomarkers market?
How will the psychiatric digital biomarkers industry grow in terms of size and CAGR by 2035?
How is continuous digital monitoring reshaping care delivery in the psychiatric digital biomarkers market?
Why is AI becoming a key growth driver in the psychiatric digital biomarkers market?
Why are wearable devices the largest type segment in the psychiatric digital biomarkers market?
Why are monitoring psychiatric digital biomarkers emerging as the fastest-growing clinical practice segment?
Why is North America leading the psychiatric digital biomarkers market?
What is driving the fastest growth in Asia Pacific’s psychiatric digital biomarkers market?
Who are the major participants shaping the psychiatric digital biomarkers landscape?
Our Clients
"The reports offered a comprehensive view of the Food and Beverage landscape, covering market trends, consumer behavior, and competitive dynamics."
"Our experience in acquiring market research reports has been outstanding — the depth of analysis and actionable insights have proven invaluable."
"Fundamental Business Insights demonstrated a keen understanding of our business needs, delivering reports tailored to our specific objectives."
Our Research Team & Methodology
Every Fundamental Business Insights report is built by a dedicated vertical research team, validated through a structured primary-and-secondary methodology, and reviewed for accuracy before it reaches you.
Research Team Overview
Prepared by the Healthcare & Medical Devices Research Team
Delivery
Published
Demand
Available
Support
Trust & Compliance
Research Domains
10 coverage areasResearch Intelligence
| Source Category | Research Sources | Purpose |
|---|---|---|
| Government Publications | Government agencies, statistical departments, regulatory bodies | Industry statistics, regulatory insights, and policy analysis |
| Company Disclosures | Annual reports, investor presentations, financial filings | Company performance, business strategy, and market positioning |
| Trade Associations | Industry associations and professional organizations | Industry developments, standards, and market perspectives |
| Technical Literature | Research papers, technical publications, academic journals | Technology developments and technical validation |
| Patent Analysis | Patent databases and intellectual property publications | Innovation trends, technology activity, and competitive research |
| Industry Databases | Established research databases and market intelligence resources | Market benchmarking, historical data, and industry analysis |
Research Workflow & Quality Assurance
Data Collection
Verified information gathered through primary and secondary research.
Data Triangulation
Cross-validation using multiple independent data sources.
Forecast Modelling
Market estimates developed using historical trends and analytical models.
Analyst Validation
Findings reviewed by domain experts for accuracy and consistency.
Editorial & Quality Review
Final editorial, quality, and compliance checks before publication.
Final Publication
Released after successful completion of the internal review process.
Report Coverage
📊 Market Assessment
- Market Size & Forecast
- Market Segmentation
- Regional Analysis
- Growth Drivers & Challenges
- Market Dynamics
🏢 Competitive Intelligence
- Competitive Landscape
- Company Profiles
- Competitive Benchmarking
- Mergers & Acquisitions
- Market Share Analysis or Key Company Strategies
🔍 Strategic Analysis
- Value Chain Analysis
- Porter's Five Forces
- PESTLE Analysis
- Pricing Trends
- Supply-Demand Analysis
🚀 Future Outlook
- Technology Landscape
- Regulatory Landscape
- Investment & Funding Landscape
- Emerging Opportunities
- Future Market Outlook
Have a question about this report or need a custom scope?
Request Customization